CHARLOTTESVILLE, Va.--(BUSINESS WIRE)--Tau Therapeutics LLC announced today that its academic collaborator, University of Virginia Professor David Schiff, MD, will present clinical trial data at the European Association of Neurosurgical Societies’ annual meeting in Tel Aviv, Israel, November 11-14, 2013. His poster, entitled “Sequential therapy with the selective T-type calcium channel blocker mibefradil and temozolomide in recurrent high-grade gliomas: An Adult Brain Tumor Consortium Study (ABTC1101),” highlights the design and progress of the dose escalation trial evaluating the safety and pharmacokinetics of lead compound mibefradil sequentially administered with temozolomide – a proprietary approach called Interlaced Therapy™.
“We are pleased to have Dr. Schiff present our ongoing Phase 1b clinical trial studying mibefradil as a potential chemotherapy enhancer in conjunction with the National Cancer Institute’s Adult Brain Tumor Consortium to the world’s leading neurosurgeons, neuro-oncologists and scientists,” said Andrew Krouse, Tau’s President and CEO. Dr. Schiff is Founder and Co-Director of UVA’s Neuro-Oncology Center. The Tel Aviv meeting is co-hosted by EANS, the American Association of Neurological Surgeons, and the Congress of Neurological Surgeons Section on Tumors.
Tau’s completed a Phase 1 dose-finding study of mibefradil in normal healthy volunteers in 2012. While Tau’s current clinical trial is in brain cancer, Tau is also considering potential Phase 2 trials in breast, lung and ovary cancers.
About Tau Therapeutics
Tau Therapeutics, a privately held oncology company based in Charlottesville, VA, is at the forefront of cancer research focusing on controlling the proliferation pathway rather than a specific protein or growth factor. Tau’s Interlaced Therapy™ is built on the rationale that using a T-type calcium channel inhibitor to increase the proportion of cancer cells and cancer stem cells at the point of maximum metabolic vulnerability in S phase will increase cell death caused by chemotherapies. By more effectively reducing tumor burden and killing the cells that cause recurrence, Tau believes it will offer a significant advancement in the treatment of cancer.
Forward-Looking Statement
This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Tau Therapeutics LLC disclaims any intent or obligation to update forward- looking statements, except as required by law.
